Lynx1 Capital Management LP is 10% Owner at Passage BIO, Inc. (PASG). They have made 12 open-market trades across 5 companies since 2023, most recently 2026-08-10.
CIK 0001910456
11 open-market purchases totalling $32.9M since 2024, against 1 sale. Across 10 scored buys the stock is up 0.4% at ninety days, and 2.4 points behind the S&P over the same stretch.
11 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| CGEM | 8,564,116 | $110.5M |
| KRRO | 1,544,980 | $13.4M |
| NEUP | 875,328 | $2.9M |
| PASG | 673,759 | $2.5M |
| TCRX | 8,019,148 | $1.9M |
| Total | $131.2M |
Shares reported on the most recent Form 4, priced at the 2026-08-13 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 55% | 45% | 50% |
| Avg Move | -0.6% | -2.3% | +0.4% |
| Alpha | -1.0% | -3.2% | -2.4% |
| Scored | 11 | 11 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KRRO | BUY | 2026-08-06 | 2026-08-13 | $11.79 | $79K | +5.1% | +7.2% | — |
| PASG | BUY | 2026-06-25 | 2026-06-29 | $4.12 | $206K | -5.9% | -8.3% | -6.1% |
| KRRO | BUY | 2026-03-31 | 2026-04-02 | $10.60 | $6K | -2.3% | -5.6% | -2.4% |
| TCRX | BUY | 2025-12-19 | 2025-12-23 | $0.90 | $218K | +17.5% | +21.6% | +6.7% |
| NEUP | BUY | 2025-10-21 | 2025-10-23 | $5.14 | $6.6M | -33.0% | -29.7% | -35.9% |
| CGEM | BUY | 2025-10-14 | 2025-10-21 | $8.35 | $2.5M | +1.6% | +2.3% | +27.6% |
| CGEM | BUY | 2025-10-08 | 2025-10-10 | $6.80 | $16.1M | +5.9% | -2.9% | +45.3% |
| PASG | BUY | 2025-07-22 | 2025-07-24 | $5.69 | $1.5M | -6.4% | +20.4% | +32.0% |
| TCRX | BUY | 2025-05-19 | 2025-05-21 | $1.20 | $4.8M | +22.4% | +0.7% | +17.5% |
| PASG | BUY | 2024-12-27 | 2024-12-31 | $0.65 | $486K | -13.4% | -15.2% | -48.8% |
| PASG | BUY | 2024-11-25 | 2024-11-27 | $0.62 | $548K | +1.6% | -15.8% | -32.4% |
| TCRX | SELL | 2023-05-31 | 2023-06-02 | $2.52 | $64K | -2.2% | -12.8% | -12.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.